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Purpose: Lidocaine is a common local anesthetic and antiarrhythmic drug that acts via the local anesthetic effect 
of blocking voltage-gated sodium channels in peripheral neurons. To evaluate lidocaine as a therapeutic agent, we 
investigated optimal concentrations and effects of intravesical lidocaine instillation in a bladder outlet obstruction 
(BOO)-induced rat model of overactive bladder (OAB).
Materials and Methods: To determine the therapeutic dosage of lidocaine, 16 female Sprague-Dawley (SD) rats 
(mean weight = 200 ± 20 g) were divided into four treatment groups: those receiving saline, 0.5% lidocaine, 1% 
lidocaine, and 2% lidocaine (n = 4 per group). Twenty-four additional SD rats were divided into two groups to 
investigate the effect of 1% lidocaine treatment in rats with BOO and normal rats (n = 12 per group). Cystometry 
was performed by infusing physiological saline and lidocaine into the bladder at a slow infusion rate (0.04 mL/
min). Cystometric parameters were analyzed using PowerLab®. The expression of c-Fos, a protein expressed by 
C-fibers in the spinal cord (L6), was investigated via western blotting.
Results: Among the test lidocaine doses, only 1% lidocaine increased the intercontraction interval (ICI) (control 
mean = 500.56 ± 24.4 s; treatment mean = 641.0 ± 49.3 s; p < .01) without changes in threshold pressure and basal 
pressure. In the BOO-induced OAB group, the ICI increased significantly after instillation of 1% lidocaine (con-
trol mean = 135.8 ± 12.87 s; OAB-group mean = 274.2 ± 33.21 s; p < .01). Detrusor overactivity and non-voiding 
contraction were observed in the control group but not in rats with BOO after lidocaine instillation. The expression 
of c-Fos in C-fibers in the spinal cord (L6) decreased significantly after 1% lidocaine treatment in rats with BOO.
Conclusion: Intravesical instillation of 1% lidocaine improves cystometric parameters without deterioration of 
contractility by blocking excessive C-fiber activity in the rat model of BOO-induced OAB. Therefore, instillation 
of 1% lidocaine has minimal effects on normal nerves while blocking nerves that contribute to OAB. Our findings 
suggest that intravesical instillation of 1% lidocaine is a useful treatment for OAB. 
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INTRODUCTION
Overactive bladder (OAB) is a storage and voiding dysfunction related to urinary urgency, with or 
without urgency incontinence, frequency, and nocturia.
(1-4) The OAB symptoms are caused either by obstruc-
tion of, or secondary effects of obstruction on the blad-
der. In some patients, the symptoms are accompanied 
by uncontrolled contractions of the detrusor muscle 
during bladder filling, known as detrusor overactivity 
(DO).(5-7) Prior investigations have shown that myelinat-
ed Aδ-fibers and unmyelinated C-fibers of the afferent 
nerve are important for the regulation of micturition. 
C-fibers convey input signals from the periphery to the 
central nervous system; these fibers respond to mechan-
ical, thermal, and chemical stimuli.(8,9) The activation of 
C-fibers, which are silent in normal bladders, is regard-
ed as a major cause of OAB, triggering micturition in 
unstable bladders.(10) We surveyed neuroinhibitors that 
might specifically inhibit only activated C-fibers during 
OAB. These included lidocaine, a common local anes-
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thetic and antiarrhythmic drug(11-13) that blocks the in-
flux of sodium ions through direct binding of neuronal 
voltage-gated sodium membrane channels, thereby pro-
ducing an analgesic effect by inhibiting the excitation 
of nerve endings or by blocking conduction in periph-
eral nerves.(14,15) In addition, lidocaine is a widely used 
local anesthetic because of its rapid onset of action and 
intermediate duration of efficacy.(12,16) In previous re-
ports, intravesical instillation of lidocaine was shown to 
provide immediate relief of pain, as well as improve ur-
gency and frequency, in patients with interstitial cysti-
tis/bladder pain syndrome.(13,17) Yokoyama et al. report-
ed that lidocaine blocked the action potentials of small 
unmyelinated C-fibers more easily than those of large 
myelinated Aδ-fibers.(14) 
The effects of intravesical lidocaine instillation for ther-
apeutic treatment of OAB have not been elucidated. Li-
docaine is a candidate drug for OAB treatment because 
it has already been approved for clinical use as an anes-
thetic, and its safety has been established(18). Therefore, 
we evaluated various doses of lidocaine in normal rats 
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to detect concentrations that could inhibit only C-fibers 
without affecting Aδ-fibers. In addition, we confirmed 
the therapeutic effect of selected lidocaine doses in a 





Six-week-old female Sprague-Dawley (SD) rats (mean 
weight = 200 ± 20 g) purchased from Orient Bio 
(Seongnam, Korea) were cared for in accordance with 
guidelines of the Association for Assessment and Ac-
creditation of Laboratory Animal Care International. 
The Institutional Animal Care and Use Committee of 
Yonsei University College of Medicine (Seoul, Korea) 
approved these animal experiments.
Sixteen SD rats were divided into the following four 
groups (n = 4 per group) to determine the optimum lido-
caine dose: the control group and groups that received 
0.5%, 1%, and 2% lidocaine. Twenty-four additional 
SD rats were divided into the following two groups 
(n = 12 per group): the control group with normal rats 
and the group of rats with BOO. BOO was induced by 
using methods described in a previous study.(2) Brief-
ly, rats were anesthetized with a mixture of Zoletil (30 
mg/kg; Virbac, Carros Cedex, France) and Rompun 
(10 mg/kg; Bayer Korea Ltd., Seoul, Korea), and the 
bladder and proximal urethra were exposed via a lower 
midline abdominal incision. The proximal urethra was 
carefully freed from the vaginal wall to avoid injury to 
periurethral blood vessels. A polyethylene-50 (PE-50) 
catheter (Clay Adams, Parsippany, NJ, USA) with an 
inner diameter of 1.40 mm was inserted into the ure-
thra. The proximal urethra was then tied loosely with 
3/0 silk, thus enabling the catheter to move freely. Af-
ter the catheter was removed, intramuscular antibiotics 
were injected postoperatively. The silk ligatures were 
removed from the rats with BOO before cystometry.
Cystometry
The cystometry study design is shown in Figure 1. Two 
animal experiments were performed: determination of 
optimum lidocaine concentration and evaluation of ef-
fects of 1% lidocaine on BOO. At 4 weeks after BOO 
surgery, rats were anesthetized with a mixture of Zoletil 
Figure 1. Schematic illustration of the design of the current study. 
A) Cystometry for determination of lidocaine concentration. B) Cystometry after instillation of 1% lidocaine in rats with bladder outlet 
obstruction (BOO)-induced overactive bladder (OAB).
Figure 2. Cystometric analysis of lidocaine dosage in normal rats. 
Cystometric parameters were analyzed for rats instilled with saline 
(A), 0.5% lidocaine (B), 1% lidocaine (C), and 2% lidocaine (D). 
Room-temperature saline or lidocaine was instilled by the intra-
vesical route for 30 min (0.04 mL/min). In the lidocaine-treatment 
groups, lidocaine was replaced with saline for 2 h. Intercontraction 
intervals (ICIs) increased in rats instilled with 0.5% (A) and 1% 
lidocaine (B), compared with rats instilled with saline instillation 
(C); however, BP, TP, and MP values did not differ significantly 
among groups. D) In rats instilled with 2% lidocaine, all cysto-
metric parameters increased relative to those of rats instilled with 
saline.
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and Rompun (1 mL/kg), and the bladder was exposed. 
A PE-50 tube, filled with saline and with its end flared 
by heat, was inserted into the bladder through the dome 
and the 3/0 silk ligatures were released. After the ab-
dominal incision was closed, the rats were placed in a 
restraining cage and allowed to recover from anesthesia 
for 2–3 h until they awakened. The catheter was con-
nected to a pressure transducer and syringe pump via a 
three-way stopcock. Cystometry was performed by in-
fusing physiological saline into the bladders of normal 
rats and rats with BOO at a slow infusion rate (0.04 
mL/min). Cystometric variables were measured dur-
ing saline infusion for 2 h to evaluate bladder function. 
After a minimum number of stable micturition cycles 
was analyzed, the saline was replaced with lidocaine 
hydrochloride (Jeil Pharmaceutical, Daegu, Korea) and 
infusion was continued for 30 min. The intravesical li-
docaine was washed out for 30 min and bladder pres-
sure was immediately monitored using a PowerLab®/
LabChart7 instrument (ADInstruments, Bella Vista, 
Australia). Continuous cystometry was performed, and 
at least five reproducible micturition cycles were ana-
lyzed. Intercontraction intervals (ICIs) were defined 
as the intervals between large amplitude spontaneous 
bladder contractions. Threshold pressure (TP) was de-
fined as the bladder pressure immediately prior to mic-
turition, relative to basal pressure (BP; the lowest blad-
der pressure during filling). Micturition pressure (MP) 
was defined as the maximum bladder pressure during 
micturition.
Drug administration
The stock solution of 2% lidocaine hydrochloride (Jeil 
Pharmaceutical) was neutralized by mixing it with 8.4% 
sodium bicarbonate solution (Jeil Pharmaceutical) at a 
1:1 ratio. To generate 1% and 0.5% lidocaine solutions, 
2% lidocaine was diluted with normal saline at 1:1 and 
1:2 ratios, respectively. The pH of neutralized lidocaine 
was between 7.4 and 7.6.
Western blotting
Spinal cord tissues were homogenized using PRO-
PREP lysis buffer (Intron, Seoul, Korea), and the con-
centration of cellular protein was determined using the 
Bio-Rad assay reagent (Bio-Rad, Hercules, CA, USA). 
Briefly, samples with equal concentrations of cellular 
protein were mixed with 4Ι sample buffer (GenDEPOT 
Inc., Barker, TX, USA), heated at 95°C for 10 min, and 
separated using electrophoresis on 10% sodium dode-
cyl sulfate–polyacrylamide gels. Proteins were then 
transferred onto polyvinylidene difluoride membranes 
(Amersham Life Science, Arlington Heights, IL, USA) 
in tris-glycine transfer buffer (InvitrogenTM, Carlsbad, 
CA, USA). The membranes were blocked for 1 h at 
room temperature with 5% skim milk in tris-buffered 
saline with Tween-20. The membranes were incubat-
ed at 4°C overnight with anti-c-Fos antibody (Santa 
Cruz Biotechnology, Santa Cruz, CA, USA), and then 
incubated with horseradish peroxidase-conjugated an-
ti-mouse IgG (Santa Cruz Biotechnology) for 1 h at 
room temperature. The membranes were washed and 
then incubated using a West-Q Chemiluminescent Sub-
strate Plus kit (GenDEPOT Inc.). The intensities of pro-
tein bands were determined using Multi Gauge software 
(version 3.0; Fuji Photo Film, Tokyo, Japan); relative 
densities were expressed as ratios of control values.
Statistical Analysis 
Quantitative data are expressed as the means ± stand-
ard deviations. Differences between lidocaine-concen-
tration groups were evaluated using one-way ANOVA 
analysis of variance followed by Dunnett’s T3 and mul-
tiple comparison post hoc tests. Paired Student’s t-tests 
were used to compare cystometric parameters before 
and after 1% lidocaine treatment. Differences with P 
values < .05 were considered statistically significant. 
Statistical analyses were performed using GraphPad 
Prism software (version 5.01; GraphPad Inc., La Jolla, 
CA, USA).
RESULTS
Cystometry for determination of lidocaine 
concentration 
The ICI increased significantly in rats instilled with 
1% and 2% lidocaine, compared with that of rats in-
stilled with saline, indicating that a relatively high 
concentration of lidocaine delayed micturition. BP and 
TP increased significantly in rats instilled with 2% li-
docaine, compared with those of control rats; BP and 
TP values in the other groups were nearly identical to 
those of the control group. The MP trend differed from 
those of other cystometric parameters-MP increased in 
rats instilled with 0.5% lidocaine but decreased in rats 
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    Saline  0.5% lidocaine 1% lidocaine 2% lidocaineCystometric 
parameters    
ICI (Intercontraction interval, s)  500.5 ± 24.4  606.3 ± 45.2  641.0 ± 49.3** 598.6 ± 26.4**
BP(Basal pressure, cmH
2
O)  3.28 ± 0.19  2.51 ± 0.31  3.49 ± 0.19  5.17 ± 0.40***
TP (Threshold pressure, cmH
2
O)  5.83 ± 0.37  6.61 ± 0.85  5.97 ± 0.55  7.45 ± 0.64*
MP (Micturition pressure, cmH
2
O)  21.69 ± 0.61  28.73 ± 2.15*** 21.09 ± 0.50  18.71 ± 0.74**
Table 1. Cystometric parameters after instillation of various concentrations of lidocaine in normal rats.
Data are shown as the means ± standard deviations. *, p < .05 compared with the control; **, p < .01; ***, p < .001
    Normal  Normal/lidocaine BOO  BOO/lidocaine
Cystometric parameters    
ICI (Intercontraction interval, s)  358.2 ± 70.02 508.9 ± 71.03** 135.8 ± 12.87 274.2 ± 33.21**
BP (Basal pressure, cmH
2
O)  3.56 ± 0.58  3.32 ± 0.63  5.35 ± 0.32  5.71 ± 0.62
TP (Threshold pressure, cmH
2
O)  9.02 ± 0.77  11.28 ± 1.59  10.16 ± 0.66  12.86 ± 1.75
MP (Micturition pressure, cmH
2
O)  23.36 ± 1.39  24.58 ± 0.65  34.29 ± 5.23  36.98 ± 4.93
Data are shown as the means ± standard deviations. **, p < .01.
 Table 2. Cystometric parameters of normal rats and rats with bladder outlet obstruction (BOO) after instillation of 1% lidocaine.
instilled with 2% lidocaine. Furthermore, instillation of 
1% lidocaine had no effect on MP (Table 1; Figure 2). 
Thus, instillation of 1% lidocaine had minimal effects 
on most cystometric parameters in normal rats and only 
increased micturition interval.
Cystometric parameters in normal rats and the 
BOO-induced rat model of OAB
At 4 weeks postoperatively, the mean ICI was signifi-
cantly shorter in rats with BOO, such that the frequen-
cy of micturition was more than two times greater than 
normal in rats with BOO. BP, TP, and MP increased in 
rats with BOO, but these differences were not statisti-
cally significant (Table 2).
Cystometry after instillation of 1% lidocaine in 
the BOO-induced rat model of OAB
After instillation of 1% lidocaine, the mean ICI of the 
BOO group was significantly longer than that of the 
BOO group before lidocaine treatment; BP, TP, and 
MP did not differ significantly between groups (Table 
2). Cystometric analysis indicated that instillation of 
1% lidocaine induced recovery of frequent micturition. 
In addition, persistent DO and non-voiding overac-
tivity disappeared after intravesical instillation of 1% 
lidocaine in rats with BOO (Figure 3). Although the 
instillation of 1% lidocaine seemed to have no effects 
on BP, TP, and MP according to parametric analysis, 
it has been shown via graph monitoring to have more 
influence on these parameters and improve the urina-
tion interval. 
Expression of c-Fos in the BOO-induced rat 
model of OAB
Expression of c-Fos was analyzed via western blotting. 
In this analysis, the intensities of the blots were deter-
mined via densitometric scanning, and relative densities 
were expressed as ratios relative to the control value. 
The results of western blotting revealed that the expres-
sion of c-Fos proteins increased in rats with BOO com-
pared with normal rats. After intravesical instillation of 
1% lidocaine, c-Fos expression decreased significantly 
in rats with BOO (Figure 4).
DISCUSSION
Persistent OAB is a urological condition that causes 
problems with urination and highly prevalent in the gen-
eral population(19-21). Prescription drugs for OAB treat-
ment, such as anticholinergics, are moderately effective 
and cause side effects that include dry mouth, consti-
pation, and drowsiness, which can limit their useful-
ness(21,22). Therefore, new therapeutic agents are needed 
to avoid the side effects of current treatments and ad-
dress the underlying causes of OAB. The activation of 
silent C-fibers is regarded as a major cause of OAB, 
as this process triggers detrusor contraction in unstable 
bladders(10,14,23). Blocking C-fiber activation may thus be 
an effective treatment for OAB patients. Previous stud-
ies showed that lidocaine is a non-selective blocker of 
voltage-gated sodium channels in peripheral neurons, 
and that unmyelinated C-fibers are more easily affected 
than myelinated Aδ-fibers(14,24). Prior investigators re-
ported that intravesical instillation of lidocaine reduces 
various symptoms of OAB and increases bladder ca-
Figure 3. The results of cystometry before and after instillation of 1% lidocaine in rats with BOO.
The mean ICI increased significantly after instillation of 1% lidocaine (B) compared with instillation of saline (A) in rats with BOO. BP, 
TP, and MP values remained unchanged. B) After instillation of 1% lidocaine, OAB symptoms and non-voiding contractions were absent.
Figure 4. Expression of c-Fos protein in the spinal cords (L6) of 
normal and BOO rats.
A) According to western blotting analysis, the expression of c-Fos 
proteins was higher in rats with BOO compared with normal rats. 
After intravesical instillation of 1% lidocaine, c-Fos expression 
decreased significantly in rats with BOO. B) Blot intensities were 
analyzed via densitometric scanning, and relative densities were 
expressed as ratios relative to control values. Data are expressed as 
the means ± standard deviations.
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pacity(10). However, intravesical instillation of lidocaine 
has not been established as a clinical treatment option 
for OAB. Therefore, we investigated lidocaine as a can-
didate for OAB treatment. In addition, lidocaine has 
been used as an anesthetic agent; because of its mech-
anism of action and stability, it may have advantages 
as a candidate therapeutic agent for clinical application. 
However, the concentration of lidocaine currently used 
in clinical applications is intended to induce anesthesia; 
thus, it simultaneously blocks both Aδ-fibers and C-fib-
ers. To evaluate the feasibility of treating OAB with li-
docaine, an adequate concentration is needed to block 
C-fibers without affecting Aδ-fibers.
We investigated changes in bladder sensation during 
cystometry after intravesical instillation of 0.5%, 1%, 
and 2% lidocaine. After the instillation of 2% lidocaine, 
the ICI, BP, and TP increased significantly, whereas 
MP decreased. Thus, intravesical instillation of 2% lido-
caine may cause serious disturbances in the contraction 
of bladder smooth muscle; it may block both sensory 
and motor neurons and is therefore an excessive dose. 
We propose that instillation of 2% lidocaine should be 
limited to use as an anesthetic, rather than as a thera-
peutic agent for treatment of OAB. Following instilla-
tion of 1% lidocaine, the results of cystometric analysis 
revealed that the ICI increased significantly, whereas 
other parameters did not differ significantly. This sug-
gests that instillation of 1% lidocaine reduces the sen-
sation of bladder filling by blocking sensory neurons. 
Previous studies have indicated that desensitization of 
C-fibers does not affect cystometric parameters or blad-
der capacity in normal individuals(25,26), but we found 
that cystometric parameters changed after intravesical 
instillation of lidocaine in our experiment. We presume 
that our findings were related to the ability of lidocaine 
to effectively block both myelinated Aδ-fibers and un-
myelinated C-fibers because it is a non-selective sodi-
um-channel blocker. Hence, our results suggest that 1% 
lidocaine blocks the action potentials of sensory neu-
rons and is therefore a suitable concentration for thera-
peutic treatment of OAB. 
To demonstrate the therapeutic effect of intravesical in-
stillation of 1% lidocaine on OAB, cystometry was per-
formed at 4 weeks after BOO induction of OAB in a rat 
model. The results of cystometric analysis showed that 
ICIs were significantly longer in rats with BOO treat-
ed with lidocaine than in non-treated rats with BOO, 
whereas BP, TP, and MP did not differ significantly dif-
ferent between groups. Cystometric monitoring showed 
that the voiding pattern after instillation of 1% lido-
caine was very similar to that of normal voiding con-
tractions. Persistent DO and non-voiding overactivity, 
which were present in the BOO-induced OAB group, 
disappeared after instillation of 1% lidocaine. Edlund et 
al. reported that the voiding pattern instability in OAB 
patients was markedly reduced after intravesical in-
stillation of lidocaine(28). Therefore, our current results 
suggest that intravesical instillation of 1% lidocaine is 
an attractive treatment for OAB based on its ability to 
block voltage-gated sodium channels in C-fibers. For 
clinical trials, the establishment of a suitable lidocaine 
concentration lower than that needed for anesthesia is 
necessary.
To confirm whether instillation of 1% lidocaine blocks 
the activation of C-fibers, we investigated the expres-
sion of c-Fos protein, a known C-fiber marker, before 
and after instillation of 1% lidocaine. Western blotting 
analysis showed that the expression of c-Fos protein in-
creased in rats with BOO, compared with normal rats; 
c-Fos expression decreased significantly after instil-
lation of 1% lidocaine in rats with BOO. Our results 
suggested that the activation of unmyelinated C-fibers 
might be associated with DO in the BOO model, and 
that instillation of 1% lidocaine might improve DO by 
blocking voltage-gated sodium channels in unmyelinat-
ed C-fibers. The instillation of 1% lidocaine may be an 
effective treatment option for use in clinical settings. 
Moreover, the effects of intravesical instillation of li-
docaine are limited to the bladder, thereby avoiding 
the development of side effects associated with current 
medications used for treatment of OAB. Instillation of 
lidocaine is relatively inexpensive, which may reduce 
medical costs for patients with OAB. Notably, patients 
can perform self-instillation of lidocaine by using clean 
intermittent catheterization.
Importantly, our study had some limitations. We did 
not evaluate the duration of the effects of instillation 
of 1% lidocaine. The frequency of instillation needed 
for a therapeutic effect is important for patients with 
OAB. In future studies, it will be necessary to evaluate 
the tolerance and adverse effects of repeated instillation 
of lidocaine. 
CONCLUSIONS
Lidocaine is widely used in clinical fields as an anes-
thetic but has not been regarded as a therapeutic agent. 
In the current study, we investigated lidocaine instilla-
tion at various concentrations for OAB treatment and 
demonstrated its effectiveness. We found that instil-
lation of 1% lidocaine has minimal effects on normal 
urination and alleviates symptoms of OAB via blocking 
voltage-gated sodium channels in unmyelinated C-fib-
ers. Although further evaluation is needed to support its 
use in clinical applications, instillation of 1% lidocaine 
may constitute a new strategy for OAB treatment.
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